RECRUITINGPhase 3INTERVENTIONAL
A Study to Evaluate the Efficacy and Safety of AD-224
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension
About This Trial
The purpose of this study is to evaluate the efficacy and safety of AD-224
Who May Be Eligible (Plain English)
Who May Qualify:
- Signed willing to sign a consent form
- Patients with Essential Hypertension
- Other inclusions applied
Who Should NOT Join This Trial:
- Patient with Secondary Hypertension
- Other exclusions applied
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Signed informed consent
* Patients with Essential Hypertension
* Other inclusions applied
Exclusion Criteria:
* Patient with Secondary Hypertension
* Other exclusions applied
Treatments Being Tested
DRUG
AD-224A
PO, Once daily, 8weeks
DRUG
AD-224B
PO, Once daily, 8weeks
DRUG
AD-224C
PO, Once daily, 8weeks
DRUG
Placebo of AD-224A
PO, Once daily, 8weeks
DRUG
Placebo of AD-224B
PO, Once daily, 8weeks
DRUG
Placebo of AD-224C
PO, Once daily, 8weeks
Locations (1)
Seoul National University Bundang Hospital
Seongnam-si, South Korea